We are live on ! Find out more
AXSM icon

Axsome Therapeutics
AXSM

244 hedge funds and large institutions have $3.12B invested in Axsome Therapeutics in 2023 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 70 increasing their positions, 88 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

92% more call options, than puts

Call options by funds: $79.2M | Put options by funds: $41.4M

83% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 24

30% more funds holding in top 10

Funds holding in top 10: 10 → 13 (+3)

18% more capital invested

Capital invested by funds: $2.65B → $3.12B (+$473M)

8% more funds holding

Funds holding: 226 → 244 (+18)

2.6% more ownership

Funds ownership: 80.28% → 82.88% (+2.6%)

20% less repeat investments, than reductions

Existing positions increased: 70 | Existing positions reduced: 88

Holders
244
Holders Change
+18
Holders Change %
+7.96%
% of All Funds
3.56%
Holding in Top 10
13
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+30%
% of All Funds
0.19%
New
44
Increased
70
Reduced
88
Closed
24
Calls
$79.2M
Puts
$41.4M
Net Calls
+$37.9M
Net Calls Change
+$18.3M

Top Buyers

1
Morgan Stanley
Morgan Stanley
New York
+$62.9M
2
PA
Perceptive Advisors
New York
+$37.2M
3
Millennium Management
Millennium Management
New York
+$27.2M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$20.4M
5
BlackRock
BlackRock
New York
+$20.4M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$65.3M
2
NIP
Nicholas Investment Partners
California
-$20.9M
3
SCM
Soleus Capital Management
Connecticut
-$16.6M
4
Citadel Advisors
Citadel Advisors
Florida
-$13.8M
5
BI
BVF Inc
California
-$10M
Name Holding Trade Value Shares
Change 		Change in
Stake
PI
201
PEAK6 Investments
Illinois
$166K +$140K +2,091 New
MLICM
202
Metropolitan Life Insurance Company (MetLife)
New York
$163K – – –
CA
203
Clearstead Advisors
Ohio
$107K -$90.3K -1,350 -50%
QC
204
Quent Capital
New York
$96.5K – – –
HFS
205
Hantz Financial Services
Michigan
$88K – – –
CI Investments Inc
206
CI Investments Inc
Ontario, Canada
$88K +$20.7K +310 +39%
N
207
Natixis
France
$86.5K -$3.81K -57 -5%
Nisa Investment Advisors
208
Nisa Investment Advisors
Missouri
$73.3K +$334 +5 +0.5%
ASN
209
Advisory Services Network
Georgia
$61.3K +$51.5K +770 New
KBC Group
210
KBC Group
Belgium
$55K -$7.29K -109 -14%
CG
211
Cutler Group
California
$47K -$13.4K -200 -25%
National Bank of Canada
212
National Bank of Canada
Quebec, Canada
$46.2K -$3.98M -59,603 -99%
KFI
213
Key Financial Inc
Pennsylvania
$35.8K – – –
AAG
214
Armstrong Advisory Group
Massachusetts
$33.7K – – –
HNB
215
Huntington National Bank
Ohio
$27.9K +$134 +2 +0.6%
WTA
216
Washington Trust Advisors
Massachusetts
$26.3K +$22.1K +330 New
NS
217
NBC Securities
Alabama
$26K – – –
First Manhattan
218
First Manhattan
New York
$23.9K – – –
Fifth Third Bancorp
219
Fifth Third Bancorp
Ohio
$15.9K -$13.4K -200 -50%
Daiwa Securities Group
220
Daiwa Securities Group
Japan
$14K – – –
UB
221
UMB Bank
Missouri
$13K – – –
QCG
222
Quadrant Capital Group
Ohio
$10.7K -$1.94K -29 -18%
Comerica Bank
223
Comerica Bank
Texas
$9.22K +$4.28K +64 +123%
HT
224
Headlands Technologies
Illinois
$6.21K -$20.9K -312 -80%
S
225
SignatureFD
Georgia
$5.81K -$4.28K -64 -47%
7 8
9
10 11

AXSM Hedge Fund Activity: Q4 2023 in Review

244 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q4 2023, worth a combined $3.12B — up 18% from $2.65B a quarter earlier.

Buyers outnumbered sellers: 44 funds opened new AXSM positions and 24 closed out — a net gain of 20 holders — while 70 added to existing stakes and 88 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $62.9M. The largest seller was Fidelity Investments, cutting an estimated $65.3M.

  • 244 institutional investors held Axsome Therapeutics (AXSM) as of Q4 2023, up from 226 in Q3 2023.
  • Funds reported $3.12B of Axsome Therapeutics stock for Q4 2023, up 18% quarter-over-quarter.
  • 44 funds opened new Axsome Therapeutics positions in Q4 2023 and 24 closed out, a net change of +20 holders.
  • The largest Axsome Therapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $62.9M added.
  • The largest Axsome Therapeutics seller in Q4 2023 was Fidelity Investments, an estimated $65.3M sold.

Based on aggregated 13F filings for Q4 2023.